Reverse Phase Protein Arrays in cancer stem cells.

Area of Science:

• Proteogenomics and Single-Cell Analysis
• Biomarker Discovery and Validation
• Preclinical Drug Development

Background:

• Proteogenomics is advancing with single-cell technologies and digital assays for sensitive biomarker detection.
• High-throughput, cost-effective phospho-proteomics for preclinical studies often utilizes Reverse-Phase Protein Arrays (RPPA).
• RPPA has demonstrated success in biomarker discovery across various sample types, including cancer stem cells (CSCs).

Purpose of the Study:

• To provide foundational knowledge and methodological steps for implementing RPPA analysis.
• To outline an experimental setup for drug testing on CSCs using RPPA.
• To facilitate targeted phospho-proteomics for identifying novel drug targets in CSCs.

Main Methods:

• Detailed description of Reverse-Phase Protein Array (RPPA) methodology.
• Application of RPPA for targeted phospho-proteomics.
• Experimental design for drug testing on cancer stem cells (CSCs).

Main Results:

• Successful application of RPPA for biomarker discovery in diverse biological samples.
• Demonstration of RPPA's utility in preclinical settings, particularly with CSCs.
• Establishment of a framework for RPPA-based drug testing on CSCs.

Conclusions:

• RPPA remains a valuable tool for cost-effective, high-throughput phospho-proteomics in preclinical research.
• This methodological article serves as a guide for deploying RPPA in CSC drug discovery.
• RPPA facilitates the identification of novel drug targets and therapeutic strategies for cancer.